Save time and get answers to complex questions with AI chat
Zemdri plazomicin nce gain exclusivity 2028 patent 2031?Novartis patent term dabrafenib?Campath litigation germany?Does lipitor's effectiveness decrease with high fat meals?Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
See the DrugPatentWatch profile for venetoclax
Data protection for venetoclax (AbbVie’s product is marketed as Venclyxto) is shown as expiring in January 2027. [1]
Data protection expiration does not necessarily equal the end of all exclusivity. Depending on the country and the specific type of protection (e.g., patent vs. data exclusivity), additional rights can extend market exclusivity beyond data protection.
The January 2027 data protection expiry is listed in DrugPatentWatch.com’s coverage for venetoclax (Venclyxto). [1] Sources: [1] https://www.drugpatentwatch.com/p/venclyxto-data-protection-2027/
Other Questions About Venetoclax :